银茶复方抑制实验性兔动脉粥样硬化的药效学研究
|
摘要
目的:在成功建立兔动脉粥样硬化模型的基础上,通过观察实验兔血脂水平、动脉粥样硬化斑块的面积、主动脉核转录因子、金属基质蛋白酶-2表达水平的变化等,研究银茶复方抗动脉粥样硬化的药效学作用及探讨其作用机制,比较了银茶复方及其组方成分茶多酚与银杏叶提取物对动脉粥样硬化作用的差异,为研究该复方制剂的物质基础和临床治疗提供理论依据。
方法:雄性新西兰白兔35只随机均分为7组,分别为:正常对照组、模型组、银茶复方高剂量组、银茶复方低剂量组、辛伐他汀组、茶多酚组和银杏叶提取物组。正常对照组喂食普通饲料,其它组喂食高脂饲料,银茶复方高剂量组、银茶复方低剂量组、辛伐他汀组、茶多酚组和银杏叶提取物组同时每天灌胃银茶复方、银茶复方、辛伐他汀、茶多酚、银杏叶提取物各500mg/﹒kg-1﹒d-1、200mg﹒kg-1﹒d-1、5mg﹒kg-1﹒d-1、250mg﹒kg-1﹒d-1、250mg﹒kg-1﹒d-1,共喂养10周。于实验前、实验结束时检测血清TC、TG、LDL-C、HDLC、MDA、SOD并计算动脉粥样硬化指数;HE染色和MASSON染色观察主动脉组织形态学变化;图像分析软件测定主动脉内膜厚度、中膜厚度、内膜厚度/中膜厚度及粥样斑块面积百分比;免疫组织化学法检测主动脉粥样硬化斑块中NF-ΚB、MMP-2的蛋白表达,RT-PCR检测主动脉粥样硬化斑块中MMP-2的mRNA表达。
结果:实验结束时,除对照组外的其它各组TC、TG、LDL-C、HDLC、MDA、SOD显著增高,主动脉见典型脂质条纹,局部斑块形成,病变处NF-ΚB、MMP-2显著表达。与模型组相比,①银茶复方高剂量组、银茶复方低剂量组血脂水平改善,内膜厚度显著减轻,粥样斑块面积减少,NF-ΚB、MMP-2的表达减少(P<0.05),银茶复方高剂量组与银茶复方低剂量组相比上述改善更为明显(P<0.05);②茶多酚组、银杏叶提取物组血脂水平改善,内膜厚度显著减轻,粥样斑块面积减少,减少NF-ΚB、MMP-2的表达(P<0.05),茶多酚组较银杏叶提取物组作用更为明显(P<0.05),以茶多酚与银杏叶提取物联合的银茶复方疗效更加显著(P<0.05)。
结论:银茶复方可通过调节血脂水平、抑制氧化反应、稳定斑块、抑制体内局部炎症反应达到抑制动脉粥样硬化病变的作用;银茶复方对动脉粥样硬化的抑制作用有一定的剂量效应;银茶复方中对抑制动脉粥样硬化起主要作用的单方是茶多酚,银杏叶提取物起辅助性作用。
Objectives:To investigate the ability of anti-atherosclerosis of Yincha compound by observe changes the serum lipid levels, the area of plaque,the expression of nuclear factor kappaB and matrix metalloproteinase-2,and then to ascertain its mechanisms,and compare the effect of tea polyphenols and inko biloba extract so as to provide the therapeutic basis to material research and clinical coronary disease.
Methods:Thirty five male New Zealand rabbits were randomly allocated into five equal groups:NC group;AS group;YCH group;YCL group;Sim group;TP group and GBE group.The NC group were fed with basis forage,the rest were fed with high-fat gorage.The NC group,AS group,YCH group,YCL group,Sim group,TP group and GBE group were independently given Yincha compound, Yincha compound, Simvastatin, tea polyphenols,ginko biloba extract 500mg/﹒kg-1﹒d-1、200mg﹒kg-1﹒d-1、5mg﹒kg-1﹒d-1、250mg﹒kg-1﹒d-1、250mg﹒kg-1﹒d-1 , They were fed for 10 weeks in all.Serum levels were examined before experiment and at the end of 10 week and AI were calculated. The histomorphology of the aorta was observed by HE stain and MASSON stain.The IT,MT,I/M and atherosclerotic area ratio were measured by image analysis software. The protein expression of NF-κB,MMP-2were detected by immunohistochemitry staining.The mRNA levels of MMP-2 were detected by RT-PCR.
Results:At the end of 10 weeks, In all high cholesterol-fed rabbits,serum lipid level increased remarkly, The typical fatty streaks and early atheromatous Plaque on the aorta have been formed and the expression of NF-ΚB and MMP-2 in the lesion were inereased significantly. Compare to atherosclerosis group:①the thickeness of intima and media,and the area of atheromatous Plaque were lower in YCH group and YCL group,especially in YCH group(P<0.05);②the thickeness of intima and media,and the area of atheromatous Plaque were lower in TP group and GBE group,especially in TP group,and the comnination of both of them gain a best effect(P<0.05).
Conclusions:Yincha compound prevent the development of atherosclerosis through lowering lipid level, oxidizing reaction,stabilizing plaque and inhibiting inflammatory reaction.
方法:雄性新西兰白兔35只随机均分为7组,分别为:正常对照组、模型组、银茶复方高剂量组、银茶复方低剂量组、辛伐他汀组、茶多酚组和银杏叶提取物组。正常对照组喂食普通饲料,其它组喂食高脂饲料,银茶复方高剂量组、银茶复方低剂量组、辛伐他汀组、茶多酚组和银杏叶提取物组同时每天灌胃银茶复方、银茶复方、辛伐他汀、茶多酚、银杏叶提取物各500mg/﹒kg-1﹒d-1、200mg﹒kg-1﹒d-1、5mg﹒kg-1﹒d-1、250mg﹒kg-1﹒d-1、250mg﹒kg-1﹒d-1,共喂养10周。于实验前、实验结束时检测血清TC、TG、LDL-C、HDLC、MDA、SOD并计算动脉粥样硬化指数;HE染色和MASSON染色观察主动脉组织形态学变化;图像分析软件测定主动脉内膜厚度、中膜厚度、内膜厚度/中膜厚度及粥样斑块面积百分比;免疫组织化学法检测主动脉粥样硬化斑块中NF-ΚB、MMP-2的蛋白表达,RT-PCR检测主动脉粥样硬化斑块中MMP-2的mRNA表达。
结果:实验结束时,除对照组外的其它各组TC、TG、LDL-C、HDLC、MDA、SOD显著增高,主动脉见典型脂质条纹,局部斑块形成,病变处NF-ΚB、MMP-2显著表达。与模型组相比,①银茶复方高剂量组、银茶复方低剂量组血脂水平改善,内膜厚度显著减轻,粥样斑块面积减少,NF-ΚB、MMP-2的表达减少(P<0.05),银茶复方高剂量组与银茶复方低剂量组相比上述改善更为明显(P<0.05);②茶多酚组、银杏叶提取物组血脂水平改善,内膜厚度显著减轻,粥样斑块面积减少,减少NF-ΚB、MMP-2的表达(P<0.05),茶多酚组较银杏叶提取物组作用更为明显(P<0.05),以茶多酚与银杏叶提取物联合的银茶复方疗效更加显著(P<0.05)。
结论:银茶复方可通过调节血脂水平、抑制氧化反应、稳定斑块、抑制体内局部炎症反应达到抑制动脉粥样硬化病变的作用;银茶复方对动脉粥样硬化的抑制作用有一定的剂量效应;银茶复方中对抑制动脉粥样硬化起主要作用的单方是茶多酚,银杏叶提取物起辅助性作用。
Objectives:To investigate the ability of anti-atherosclerosis of Yincha compound by observe changes the serum lipid levels, the area of plaque,the expression of nuclear factor kappaB and matrix metalloproteinase-2,and then to ascertain its mechanisms,and compare the effect of tea polyphenols and inko biloba extract so as to provide the therapeutic basis to material research and clinical coronary disease.
Methods:Thirty five male New Zealand rabbits were randomly allocated into five equal groups:NC group;AS group;YCH group;YCL group;Sim group;TP group and GBE group.The NC group were fed with basis forage,the rest were fed with high-fat gorage.The NC group,AS group,YCH group,YCL group,Sim group,TP group and GBE group were independently given Yincha compound, Yincha compound, Simvastatin, tea polyphenols,ginko biloba extract 500mg/﹒kg-1﹒d-1、200mg﹒kg-1﹒d-1、5mg﹒kg-1﹒d-1、250mg﹒kg-1﹒d-1、250mg﹒kg-1﹒d-1 , They were fed for 10 weeks in all.Serum levels were examined before experiment and at the end of 10 week and AI were calculated. The histomorphology of the aorta was observed by HE stain and MASSON stain.The IT,MT,I/M and atherosclerotic area ratio were measured by image analysis software. The protein expression of NF-κB,MMP-2were detected by immunohistochemitry staining.The mRNA levels of MMP-2 were detected by RT-PCR.
Results:At the end of 10 weeks, In all high cholesterol-fed rabbits,serum lipid level increased remarkly, The typical fatty streaks and early atheromatous Plaque on the aorta have been formed and the expression of NF-ΚB and MMP-2 in the lesion were inereased significantly. Compare to atherosclerosis group:①the thickeness of intima and media,and the area of atheromatous Plaque were lower in YCH group and YCL group,especially in YCH group(P<0.05);②the thickeness of intima and media,and the area of atheromatous Plaque were lower in TP group and GBE group,especially in TP group,and the comnination of both of them gain a best effect(P<0.05).
Conclusions:Yincha compound prevent the development of atherosclerosis through lowering lipid level, oxidizing reaction,stabilizing plaque and inhibiting inflammatory reaction.
引文
[1]Moghadasian MH.Experimental atherosclerosis:a historical overriew[J].life sci, 2002, 70: 855 -865
[2]Skalen K,Gustafsson M,Rydberg EK,et al.Subendonthelial retention of atherogenic lipoproteins in early atherosclerosis[J]. Nature, 2002, 417:750-754
[3]Joyce CW,Amar MJ,Lambert G,et al.The ATP binding cassette transporter A1 (ABCA1) modulates the development of aortic atherosclerosis in C57BL/6 and apoE-knockout mice[J].Proc natl acad sci USA,2002.99:407-412
[4]Robert WC.The understanding miracle drugs:the statin drugs are to atherosclerosis what penicillin was to infectious disease.Am J cardiol, 1996,78:377-378
[5]麦筱莉,藤皋军.内皮祖细胞的特性及其在动脉粥样硬化性疾病中的作用[J].中华心血管病杂志,2007,35(8):685-689
[6]Sima AV, Stancu CS, Simionescu M.C,et al.Vascular endothelium in atherosclerosis.Cell Tissue Res. 2009 Jan,335(1):191-203
[7]Wick G,Berger P,jansen-durr P,et al.A darwinnian–evolutionary concept of age-related disease[J]. Exp Gerontol,2003,38:13-25
[8]Shah PK.Molecular mechanisms of plaque instability.Curr Opin Lipidol,2007,18 (5):492 -499
[9]Zeng B,Prasan A,Fung KC,et al.Elevated circulating levels of matrix metalloproteinase-9 and-2 in patients with symptomatic coronary artery disease[J].Inern Med J, 2005, 35(6): 331-335
[10]Romzova M,Hohenadel D,Kolostova K,et al.NFkappaB and its inhibitor IkappaB in relation to type 2 diabetes and its microvascular and atherosclerotic complications[J].Hum Immunol,2006,67(9):706-713
[11]Nobles-James C,James EA,Sowers JR.Prevention of cardiovascularr complications of diabetes mellitus by aspirin.Cardiovasc Drug Rev, 2004, 22(3):215-226
[12]杨晓云,王琳,周宁等.阿司匹林抗动脉粥样硬化作用的机制探讨[J].中华医学杂志,2007,12,46:3298-3242.
[13]Matsuo T,Iwade K,Hirata N,et al.Improvement of arterial stiffness by the antioxidant and anti-inflammatory effects of short-term statin therapy in patients with hypercholesterolemia.Heart Vessels,2005,20(1):8-12
[14]Ceconi C,Mastrorilli F,Squasi PA,et al.Efficacy of angiotensin-converting enzymeinhibitors in secondary prevention.Ital Heart J,2005,7:5-13
[15]Frances T. Yen, Olivier Roitel, Lionel Bonnard,et al.Lipolysis stimulated lipoprotein receptor: a novel molecular link between hyperlipidemia,weight gain,and atherosclerosis in mice.J Biol Chem. 2008,283(37):25650-25659
[16] Sue K Gao, Shirley AA Beresford, Laura L Frank,et al.Modifications to the Healthy Eating Index and its ability to predict obesity: the Multi-Ethnic Study of Atherosclerosis. Am J Clin Nutr. 2008 Jul;88(1):64-69
[17]Bryant MJ, Stevens J, Truesdale KP,et al.Obesity and vital exhaustion: analysis of the Atherosclerosis Risk in the Communities study. 2008, 16(7): 1545-1551
[18]Choi,SHChae,AMiller,et al. Relationship between biomarkers of oxidized low-density lipoprotein, statin therapy, quantitative coronary angiography, and atheroma:volume observations from the REVERSAL (Reversal of Atherosclerosis with Aggressive Lipid Lowering) study.J Am Coll Cardiol. 2008,52(1):24-32
[19]Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment PanelⅢguidelines[J]. Circulation, 2004, 110(2):227-239
[20]Asztalos BF.HDL Atherosclerosis Treatment Study.High dencity lipoprotein metabolism and progression of atherosclerosis:new insights from the HDL Atherosclerosis Treatment Study[J].Curr Opin Cardiol,2004,19(4):385-391
[21] Duffy D,Rader DJ.Emerging therapies targeting high-density lipoprotein metabolism and reverse cholesterol transport[J].Circulation,2006 Feb 28,113(8):1140-1150
[22]HERD JA,WEST MS,BALLANTYNE C,et al.Baseline characteristics of subjects in the Lipoprotein and Coronary Atherosclerosis Study(LCAS)ith fluvastatin[J].The American journal of cardiology,1994,14(23):42-49
[23]Herd,JA,Ballantyne C, Farmer J,et al.Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations(Lipoprotein and Coronary Atherosclerosis Study [LCAS])[J].The American Journal of Medicine, 1997, 80(3): 278 -286
[24]Ishigaki Y, Katagiri H, Gao J,et al.Impact of plasma oxidized low-density lipoprotein removal on atherosclerosis.Circulation,2008,118(1):75-83
[25]Fruebis J,Steinberg D,Dresel HA,et al.A comparison of the antiatherogenic effects of probucol and of a structural analog of probucol in LDL-receptor-deficient rabbits[J]. J Clin Invest,1994,94(1):392-39.
[26]Tardif JC,Gregoire J,LAllier PL,et al.Effects of the antioxidant succinobucol (AGI-1067) on human atherosclerosis in a randomized clinical trial. Atherosclerosis, 2008, 197 (1):480-486.
[27]李连达,李贻奎.中药研究与新药开发的回顾与展望[J].中医研究,2009,50(2):107-110
[28]陈向涛,汪惠丽,李俊.中药复方药理研究概况[J].安徽医药,2002,6(1):3
[29]罗国安,王义明.中药复方物质基础之现代研究[M].中医药新里程,1998.15(1):6-14
[30]夏云,李志明,朱丹妮,等.生脉散复方化学动态变化与药效学关系的研究-生脉散复方化学的研究[J].中国中药杂志.1998,23(4)230-231
[31]裴利霞.中药药效动力学研究[J].中医药学刊,2005,23(1):121-123
[32]沈燕,吴立军,王本祥,等.参附汤体内代谢化学成分的初步探讨[J].沈阳药科大学学报, 2001,18(1):23-26
[33]杜冠华.高通量药物筛选在新药研究中的应用[J].基础医学与临床,2001,21(4):289-293
[34]HuangXD, Kong L,Li X, et al.Strategy for analysis and screening of bioactive compounds in traditional Chinese medlicines[J].J Chranatogr B Analy Technol Bianed Life Sci, 2004, 812(12):71-84
[35]任平,熙.新概念药物的源泉之一:方剂血清靶成分[J].中草药,2000,31(8):637-638
[36]王米渠,吴斌,袁世宏.试谈复方药物分子机制研究[J].现代中西医结合杂志,2003,12(5): 449-450
[37]Zhang Y Z,Zheng X K,Bi Y F,et al.Advancement in study on material foundation of medicinal effectiveness of compound prescriptions of Chinese medicine[J].World Sci Tech-Mod Tradit Chin Med,2001,3(5):37-41
[38]Luo G A.Research approach on material foundation of medicinal effectiveness of compound prescriptions of Chinese medicine[J].Chin J Pract Chin Mod Med,2000, 13 (19):1456-1459
[39]Wu K Y,Liang G Y,Jin F Y,et al.Thoughts and methods in study on material foundation of medicinal effectiveness of compound prescriptions of Chinese medicine[J].World Sci Tech-Mod Tradit Chin Med,2003,5(6):13-17
[40]Liu J X,Ren J G.Approach on materatial foundation of medicinal effectiveness of compound prescriptions of Chinese medicine[J].Res Inf Tradit Chin Herb,2004,6(12):8-11
[41]宁黎丽,毕开顺,王瑞,等.吴茱萸汤药效物质基础的方法学研究[J].药学学报,2000, 35(2):131-134
[42]朱华旭,丁林生.白头翁汤汤剂化学成分的分离研究.中成药,1999,21(6):312-313
[43]张伯礼,高秀敏,商洪才.复方丹参方的药效物质及作用机理研究[J].世界科学技术-药现代化,2003,5(5):14-17
[44]李红梅,刘顺良,姜静岩.银杏叶提取物对心脑血管疾病的药理作用研究进展[J].时珍国医国药,2002,13(2):105-106.
[45]张星海,沈生荣,杨贤强,等.茶多酚对心脑血管疾病防治作用的研究进展[J].福建茶叶,2001,(4):24-27
[46]杨贤强,等.茶多酚化学[M].上海:上海科学技术出版社,2003.1-7
[47]何昱,洪筱坤,王智华.茶多酚中儿茶素类及咖啡因的含量测定[J].中成药,2003,25(10): 827-830
[48]赵秀兰,宫爱华,李建华.茶多酚抗动脉粥样硬化机制研究[J].中国公共卫生,2003, 19(8):930-931
[49]Yokozaw a T,Nakagawa Tl.Antioxidative activity of green tea polyphenol in cholesterol l-fed rats[J].2002,50(12):3549-3552
[50]吴文华,吴镇洲.茶多酚的抗低密度脂蛋白氧化作用[J].中国茶叶,2002,24(6):6-7
[51]Lee SR,JungCH,Lee SR,et al.The green tea polyphenol(-)-epigallocate-chin gallate and other antioxidants on lipid peroxidation ingerbil brain homogenates[J].Phytotherapy Res, 2003,17(3):206-209
[52]DAI Dezai,CHEN Shihong,FENG Yu.Tea Polyphenols and Quercetin Preventing the Heart,Brain and Liver from the Injury by Free Radicals in Comparison with Ascorbic Acid[J].Chin J Nat Med,2004,2(4):223-231
[53]杨贤强,等.茶多酚化学[M].上海:上海科学技术出版社,2003.
[54]Snkata R,Ueno T,Nakamura T,et al.Green tea polyphenol epigallocatechingallate inhibits platelet-derived growth factor-induced proliferation human hepatic stellate cell lineLI90[J].J Gepatol,2004,40(1):52-59
[55]冯磊光.茶色素对高脂血症及血液流变学异常的疗效[J].中国微循环,2002,6(6):173
[56]冯传咸,陈金和,胡宗礼,等.茶多酚对心肌缺血再灌注大鼠左心功能和血清一氧化氮及血浆内皮素的影响[J].咸宁医学院学报,2002,16(2):85-88
[57]杨丽松,周琴,李卫平.茶多酚静脉内给药对动物缺血性脑损伤的保护作用[J].大连医科大学学报,2004,26(3):170-173,176
[58]TA Van Beek,LT Taylor.Sample preparation of standarded extracts of Ginkgo biloba of supercritical fluid extraction [J].Phytochemical Analysis,1996,(7):185-189
[59]张迪清,何照范.银杏叶资源化学研究[M].北京:中国轻工业出版社,1998,21-34
[60]Hasler A,Beat Meier,Otto Sticher.Complex flavonol glycosides from the leaves of Ginkgo Biloba.Phytochemistry,1992,31(4):1391-1394
[61]肖海龙,高尔,胡晓丽.银杏叶总黄酮药理作用研究进展[J].中国药房,2005,16(12): 947- 949
[62]TERIS A,VAN B, GERRIT P. Preparative isolation and separation procedure for Ginkgolides A,B,C,Jand Bilobalide[J].J Nat Prod,1997,60(7):735-738
[63]沈嘉.特异性PAF受体拮抗药-银杏苦内酯B在PAF药理研究和临床研究上的应用[J].沈阳药科大学学报,1996,13(1):63
[64]卢鑫,高尔.银杏苦内酯药理作用的研究进展[J].中国药房,2006,17(3):221-223
[65]楼凤昌,凌娅,唐于平,王颖.银杏萜内酯的分离、纯化和结构鉴定[J].中国天然药物, 2004,2(1):11-15
[66] TA Van Beek ,L T Taylor. Sample preparation of standarded extracts of Ginkgo biloba of supercritical fluid extraction [J]. Phytochemical Analysis,1996,(7):185-189
[67]曾海涛,曾海波.近年银杏叶提取物研究进展[J].国外医学·中医中药分册,2000,22 (4):199-202
[68]律颖,贾敏江.银杏叶提取物防治冠心病的药理及临床研究[J].心脏杂志,2000,12(6): 484-485
[69]车舟,谭华炳,贺琴,肖学云.银杏叶提取物药理与心血管和神经系统实验研究进展[J].实用心脑肺血管病杂志,2006,14(4):331-334
[70]陈家欢,何萍,戴马季,黄仁彬.银杏叶提取物对实验性心肌缺血和血液流变性的影响[J].广西医科大学学报,2002,19(3):326-328
[71]高琦瑛,陈岫峰.银杏叶提取物对局灶性脑缺血模型大鼠的保护作用[J].中国药物应用与监测,2005,(3):12-13
[72]李鸣皋,马贵喜,孙运峰,等.血管紧张素-Ⅱ对急性缺氧时血管内皮细胞分泌内皮素的影响及金钠多的保护作用研究[J].中国全科医学,2005,8(19):1575-1581
[73]陈修,刘立英,李哲夫.银杏叶提取物的心血管保护作用与一氧化氮介导的脑血管舒张作用[J].中华医学杂志,1998,78(9):692-695
[74]梁翌,杨为民,李绪兰,等.银杏叶提取物对兔血小板聚集的影响[J].中国药学杂志,2002,37(1):25-28
[75]胡波,梅元武,孙圣刚,童萼塘.银杏叶提取物对大鼠缺血再灌注皮质内氨基酸动态平衡的影响[J].脑与神经疾病杂志,2001,9(1):1-3
[76]马建林,毛焕元,等.银杏叶片防治冠心病患者体内红细胞膜脂质过氧化损伤的临床观察[J].同济医科大学学报,2000,29(1):71-73
[77]吴国星,蔡巍.金纳多对冠心病患者血液流变性和可溶性黏附分子的影响[J].浙江临床医学,2005,7(11):1192
[78]张晓刚,陈运贞,雷寒,等.茶多酚对实验性动脉粥样硬化兔脂蛋白脂酶、肝脂酶活性的影响及意义[J].中国病理生理杂志,2004,20(8):1476-1480.
[79]银杏叶对冠心病高同型半胱氨酸血脂症血小板及内皮功能影响的临床观察[J].山西中医,2000,4(4):11-13
[80]Li Z,Li L,ZieLKe H R,et a1.Increased expression of 72-kd typeⅣc ollagenase (MMP-2) in human aortic atherosclerotic lesions[J].Am J Pathol,1996,148(1):121-128.
[81]Romzova M,Hohenadel D,Kolostova K,et al.NFkappaB and its inhibitor IkappaB in relation to type 2 diabetes and its microvascular and atherosclerotic complications[J].Hum Immunol,2006,67(9):706-713.
[82]Saren P,Welgus HG,Kovanen PT.TNF-αand IL-1βselectively induce expression of 92-kDa gelatinase by human macrophages.J Immunol,1996,157(9):4159-4165.
[2]Skalen K,Gustafsson M,Rydberg EK,et al.Subendonthelial retention of atherogenic lipoproteins in early atherosclerosis[J]. Nature, 2002, 417:750-754
[3]Joyce CW,Amar MJ,Lambert G,et al.The ATP binding cassette transporter A1 (ABCA1) modulates the development of aortic atherosclerosis in C57BL/6 and apoE-knockout mice[J].Proc natl acad sci USA,2002.99:407-412
[4]Robert WC.The understanding miracle drugs:the statin drugs are to atherosclerosis what penicillin was to infectious disease.Am J cardiol, 1996,78:377-378
[5]麦筱莉,藤皋军.内皮祖细胞的特性及其在动脉粥样硬化性疾病中的作用[J].中华心血管病杂志,2007,35(8):685-689
[6]Sima AV, Stancu CS, Simionescu M.C,et al.Vascular endothelium in atherosclerosis.Cell Tissue Res. 2009 Jan,335(1):191-203
[7]Wick G,Berger P,jansen-durr P,et al.A darwinnian–evolutionary concept of age-related disease[J]. Exp Gerontol,2003,38:13-25
[8]Shah PK.Molecular mechanisms of plaque instability.Curr Opin Lipidol,2007,18 (5):492 -499
[9]Zeng B,Prasan A,Fung KC,et al.Elevated circulating levels of matrix metalloproteinase-9 and-2 in patients with symptomatic coronary artery disease[J].Inern Med J, 2005, 35(6): 331-335
[10]Romzova M,Hohenadel D,Kolostova K,et al.NFkappaB and its inhibitor IkappaB in relation to type 2 diabetes and its microvascular and atherosclerotic complications[J].Hum Immunol,2006,67(9):706-713
[11]Nobles-James C,James EA,Sowers JR.Prevention of cardiovascularr complications of diabetes mellitus by aspirin.Cardiovasc Drug Rev, 2004, 22(3):215-226
[12]杨晓云,王琳,周宁等.阿司匹林抗动脉粥样硬化作用的机制探讨[J].中华医学杂志,2007,12,46:3298-3242.
[13]Matsuo T,Iwade K,Hirata N,et al.Improvement of arterial stiffness by the antioxidant and anti-inflammatory effects of short-term statin therapy in patients with hypercholesterolemia.Heart Vessels,2005,20(1):8-12
[14]Ceconi C,Mastrorilli F,Squasi PA,et al.Efficacy of angiotensin-converting enzymeinhibitors in secondary prevention.Ital Heart J,2005,7:5-13
[15]Frances T. Yen, Olivier Roitel, Lionel Bonnard,et al.Lipolysis stimulated lipoprotein receptor: a novel molecular link between hyperlipidemia,weight gain,and atherosclerosis in mice.J Biol Chem. 2008,283(37):25650-25659
[16] Sue K Gao, Shirley AA Beresford, Laura L Frank,et al.Modifications to the Healthy Eating Index and its ability to predict obesity: the Multi-Ethnic Study of Atherosclerosis. Am J Clin Nutr. 2008 Jul;88(1):64-69
[17]Bryant MJ, Stevens J, Truesdale KP,et al.Obesity and vital exhaustion: analysis of the Atherosclerosis Risk in the Communities study. 2008, 16(7): 1545-1551
[18]Choi,SHChae,AMiller,et al. Relationship between biomarkers of oxidized low-density lipoprotein, statin therapy, quantitative coronary angiography, and atheroma:volume observations from the REVERSAL (Reversal of Atherosclerosis with Aggressive Lipid Lowering) study.J Am Coll Cardiol. 2008,52(1):24-32
[19]Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment PanelⅢguidelines[J]. Circulation, 2004, 110(2):227-239
[20]Asztalos BF.HDL Atherosclerosis Treatment Study.High dencity lipoprotein metabolism and progression of atherosclerosis:new insights from the HDL Atherosclerosis Treatment Study[J].Curr Opin Cardiol,2004,19(4):385-391
[21] Duffy D,Rader DJ.Emerging therapies targeting high-density lipoprotein metabolism and reverse cholesterol transport[J].Circulation,2006 Feb 28,113(8):1140-1150
[22]HERD JA,WEST MS,BALLANTYNE C,et al.Baseline characteristics of subjects in the Lipoprotein and Coronary Atherosclerosis Study(LCAS)ith fluvastatin[J].The American journal of cardiology,1994,14(23):42-49
[23]Herd,JA,Ballantyne C, Farmer J,et al.Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations(Lipoprotein and Coronary Atherosclerosis Study [LCAS])[J].The American Journal of Medicine, 1997, 80(3): 278 -286
[24]Ishigaki Y, Katagiri H, Gao J,et al.Impact of plasma oxidized low-density lipoprotein removal on atherosclerosis.Circulation,2008,118(1):75-83
[25]Fruebis J,Steinberg D,Dresel HA,et al.A comparison of the antiatherogenic effects of probucol and of a structural analog of probucol in LDL-receptor-deficient rabbits[J]. J Clin Invest,1994,94(1):392-39.
[26]Tardif JC,Gregoire J,LAllier PL,et al.Effects of the antioxidant succinobucol (AGI-1067) on human atherosclerosis in a randomized clinical trial. Atherosclerosis, 2008, 197 (1):480-486.
[27]李连达,李贻奎.中药研究与新药开发的回顾与展望[J].中医研究,2009,50(2):107-110
[28]陈向涛,汪惠丽,李俊.中药复方药理研究概况[J].安徽医药,2002,6(1):3
[29]罗国安,王义明.中药复方物质基础之现代研究[M].中医药新里程,1998.15(1):6-14
[30]夏云,李志明,朱丹妮,等.生脉散复方化学动态变化与药效学关系的研究-生脉散复方化学的研究[J].中国中药杂志.1998,23(4)230-231
[31]裴利霞.中药药效动力学研究[J].中医药学刊,2005,23(1):121-123
[32]沈燕,吴立军,王本祥,等.参附汤体内代谢化学成分的初步探讨[J].沈阳药科大学学报, 2001,18(1):23-26
[33]杜冠华.高通量药物筛选在新药研究中的应用[J].基础医学与临床,2001,21(4):289-293
[34]HuangXD, Kong L,Li X, et al.Strategy for analysis and screening of bioactive compounds in traditional Chinese medlicines[J].J Chranatogr B Analy Technol Bianed Life Sci, 2004, 812(12):71-84
[35]任平,熙.新概念药物的源泉之一:方剂血清靶成分[J].中草药,2000,31(8):637-638
[36]王米渠,吴斌,袁世宏.试谈复方药物分子机制研究[J].现代中西医结合杂志,2003,12(5): 449-450
[37]Zhang Y Z,Zheng X K,Bi Y F,et al.Advancement in study on material foundation of medicinal effectiveness of compound prescriptions of Chinese medicine[J].World Sci Tech-Mod Tradit Chin Med,2001,3(5):37-41
[38]Luo G A.Research approach on material foundation of medicinal effectiveness of compound prescriptions of Chinese medicine[J].Chin J Pract Chin Mod Med,2000, 13 (19):1456-1459
[39]Wu K Y,Liang G Y,Jin F Y,et al.Thoughts and methods in study on material foundation of medicinal effectiveness of compound prescriptions of Chinese medicine[J].World Sci Tech-Mod Tradit Chin Med,2003,5(6):13-17
[40]Liu J X,Ren J G.Approach on materatial foundation of medicinal effectiveness of compound prescriptions of Chinese medicine[J].Res Inf Tradit Chin Herb,2004,6(12):8-11
[41]宁黎丽,毕开顺,王瑞,等.吴茱萸汤药效物质基础的方法学研究[J].药学学报,2000, 35(2):131-134
[42]朱华旭,丁林生.白头翁汤汤剂化学成分的分离研究.中成药,1999,21(6):312-313
[43]张伯礼,高秀敏,商洪才.复方丹参方的药效物质及作用机理研究[J].世界科学技术-药现代化,2003,5(5):14-17
[44]李红梅,刘顺良,姜静岩.银杏叶提取物对心脑血管疾病的药理作用研究进展[J].时珍国医国药,2002,13(2):105-106.
[45]张星海,沈生荣,杨贤强,等.茶多酚对心脑血管疾病防治作用的研究进展[J].福建茶叶,2001,(4):24-27
[46]杨贤强,等.茶多酚化学[M].上海:上海科学技术出版社,2003.1-7
[47]何昱,洪筱坤,王智华.茶多酚中儿茶素类及咖啡因的含量测定[J].中成药,2003,25(10): 827-830
[48]赵秀兰,宫爱华,李建华.茶多酚抗动脉粥样硬化机制研究[J].中国公共卫生,2003, 19(8):930-931
[49]Yokozaw a T,Nakagawa Tl.Antioxidative activity of green tea polyphenol in cholesterol l-fed rats[J].2002,50(12):3549-3552
[50]吴文华,吴镇洲.茶多酚的抗低密度脂蛋白氧化作用[J].中国茶叶,2002,24(6):6-7
[51]Lee SR,JungCH,Lee SR,et al.The green tea polyphenol(-)-epigallocate-chin gallate and other antioxidants on lipid peroxidation ingerbil brain homogenates[J].Phytotherapy Res, 2003,17(3):206-209
[52]DAI Dezai,CHEN Shihong,FENG Yu.Tea Polyphenols and Quercetin Preventing the Heart,Brain and Liver from the Injury by Free Radicals in Comparison with Ascorbic Acid[J].Chin J Nat Med,2004,2(4):223-231
[53]杨贤强,等.茶多酚化学[M].上海:上海科学技术出版社,2003.
[54]Snkata R,Ueno T,Nakamura T,et al.Green tea polyphenol epigallocatechingallate inhibits platelet-derived growth factor-induced proliferation human hepatic stellate cell lineLI90[J].J Gepatol,2004,40(1):52-59
[55]冯磊光.茶色素对高脂血症及血液流变学异常的疗效[J].中国微循环,2002,6(6):173
[56]冯传咸,陈金和,胡宗礼,等.茶多酚对心肌缺血再灌注大鼠左心功能和血清一氧化氮及血浆内皮素的影响[J].咸宁医学院学报,2002,16(2):85-88
[57]杨丽松,周琴,李卫平.茶多酚静脉内给药对动物缺血性脑损伤的保护作用[J].大连医科大学学报,2004,26(3):170-173,176
[58]TA Van Beek,LT Taylor.Sample preparation of standarded extracts of Ginkgo biloba of supercritical fluid extraction [J].Phytochemical Analysis,1996,(7):185-189
[59]张迪清,何照范.银杏叶资源化学研究[M].北京:中国轻工业出版社,1998,21-34
[60]Hasler A,Beat Meier,Otto Sticher.Complex flavonol glycosides from the leaves of Ginkgo Biloba.Phytochemistry,1992,31(4):1391-1394
[61]肖海龙,高尔,胡晓丽.银杏叶总黄酮药理作用研究进展[J].中国药房,2005,16(12): 947- 949
[62]TERIS A,VAN B, GERRIT P. Preparative isolation and separation procedure for Ginkgolides A,B,C,Jand Bilobalide[J].J Nat Prod,1997,60(7):735-738
[63]沈嘉.特异性PAF受体拮抗药-银杏苦内酯B在PAF药理研究和临床研究上的应用[J].沈阳药科大学学报,1996,13(1):63
[64]卢鑫,高尔.银杏苦内酯药理作用的研究进展[J].中国药房,2006,17(3):221-223
[65]楼凤昌,凌娅,唐于平,王颖.银杏萜内酯的分离、纯化和结构鉴定[J].中国天然药物, 2004,2(1):11-15
[66] TA Van Beek ,L T Taylor. Sample preparation of standarded extracts of Ginkgo biloba of supercritical fluid extraction [J]. Phytochemical Analysis,1996,(7):185-189
[67]曾海涛,曾海波.近年银杏叶提取物研究进展[J].国外医学·中医中药分册,2000,22 (4):199-202
[68]律颖,贾敏江.银杏叶提取物防治冠心病的药理及临床研究[J].心脏杂志,2000,12(6): 484-485
[69]车舟,谭华炳,贺琴,肖学云.银杏叶提取物药理与心血管和神经系统实验研究进展[J].实用心脑肺血管病杂志,2006,14(4):331-334
[70]陈家欢,何萍,戴马季,黄仁彬.银杏叶提取物对实验性心肌缺血和血液流变性的影响[J].广西医科大学学报,2002,19(3):326-328
[71]高琦瑛,陈岫峰.银杏叶提取物对局灶性脑缺血模型大鼠的保护作用[J].中国药物应用与监测,2005,(3):12-13
[72]李鸣皋,马贵喜,孙运峰,等.血管紧张素-Ⅱ对急性缺氧时血管内皮细胞分泌内皮素的影响及金钠多的保护作用研究[J].中国全科医学,2005,8(19):1575-1581
[73]陈修,刘立英,李哲夫.银杏叶提取物的心血管保护作用与一氧化氮介导的脑血管舒张作用[J].中华医学杂志,1998,78(9):692-695
[74]梁翌,杨为民,李绪兰,等.银杏叶提取物对兔血小板聚集的影响[J].中国药学杂志,2002,37(1):25-28
[75]胡波,梅元武,孙圣刚,童萼塘.银杏叶提取物对大鼠缺血再灌注皮质内氨基酸动态平衡的影响[J].脑与神经疾病杂志,2001,9(1):1-3
[76]马建林,毛焕元,等.银杏叶片防治冠心病患者体内红细胞膜脂质过氧化损伤的临床观察[J].同济医科大学学报,2000,29(1):71-73
[77]吴国星,蔡巍.金纳多对冠心病患者血液流变性和可溶性黏附分子的影响[J].浙江临床医学,2005,7(11):1192
[78]张晓刚,陈运贞,雷寒,等.茶多酚对实验性动脉粥样硬化兔脂蛋白脂酶、肝脂酶活性的影响及意义[J].中国病理生理杂志,2004,20(8):1476-1480.
[79]银杏叶对冠心病高同型半胱氨酸血脂症血小板及内皮功能影响的临床观察[J].山西中医,2000,4(4):11-13
[80]Li Z,Li L,ZieLKe H R,et a1.Increased expression of 72-kd typeⅣc ollagenase (MMP-2) in human aortic atherosclerotic lesions[J].Am J Pathol,1996,148(1):121-128.
[81]Romzova M,Hohenadel D,Kolostova K,et al.NFkappaB and its inhibitor IkappaB in relation to type 2 diabetes and its microvascular and atherosclerotic complications[J].Hum Immunol,2006,67(9):706-713.
[82]Saren P,Welgus HG,Kovanen PT.TNF-αand IL-1βselectively induce expression of 92-kDa gelatinase by human macrophages.J Immunol,1996,157(9):4159-4165.